Format

Send to

Choose Destination
Drugs. 2018 May;78(7):787. doi: 10.1007/s40265-018-0910-x.

Correction to: Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.

Author information

1
Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada. ggzhanel@pcs.mb.ca.
2
Department of Medicine, Winnipeg Health Sciences Centre, MS673-820 Sherbrook Street, Winnipeg, Manitoba, R3A 1R9, Canada. ggzhanel@pcs.mb.ca.
3
College of Pharmacy, University of Manitoba, Winnipeg, Canada.
4
Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada.
5
Diagnostic Services Manitoba, Winnipeg, Canada.
6
Department of Chemistry, Faculty of Science, University of Manitoba, Winnipeg, Canada.
7
Department of Medicine, Winnipeg Health Sciences Centre, MS673-820 Sherbrook Street, Winnipeg, Manitoba, R3A 1R9, Canada.
8
Department of Pharmacy, Winnipeg Health Sciences Centre, Winnipeg, Canada.
9
Division of Pulmonary, Critical Care, Allergy and Clinical Immunology, The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

Abstract

Section heading 5.2, which currently reads 5.2 Meropenem-Relebactam.

PMID:
29748749
DOI:
10.1007/s40265-018-0910-x

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center